Cargando…

cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases

“clinical NEUroPROteomics of neurodegenerative diseases” (cNEUPRO) is a Specific Targeted Research Project (STREP) within the sixth framework program of the European Commission dedicated to the search for novel biomarker candidates for Alzheimer's disease and other neurodegenerative diseases. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spitzer, Philipp, Klafki, Hans Wolfgang, Blennow, Kaj, Buée, Luc, Esselmann, Hermann, Herruka, Sanna-Kaisa, Jimenez, Connie, Klivenyi, Peter, Lewczuk, Piotr, Maler, Juan Manuel, Markus, Katrin, Meyer, Helmut E., Morris, Chris, Müller, Thorsten, Otto, Markus, Parnetti, Lucilla, Soininen, Hilkka, Schraen, Susanna, Teunissen, Charlotte, Vecsei, Laszlo, Zetterberg, Henrik, Wiltfang, Jens
Formato:	Texto
Lenguaje:	English
Publicado:	SAGE-Hindawi Access to Research 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945639/ https://www.ncbi.nlm.nih.gov/pubmed/20886057 http://dx.doi.org/10.4061/2010/548145

Ejemplares similares

Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?
por: Parnetti, Lucilla, et al.
Publicado: (2010)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
por: Teunissen, Charlotte E., et al.
Publicado: (2018)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

Phagocytosis and LPS alter the maturation state of β-amyloid precursor protein and induce different Aβ peptide release signatures in human mononuclear phagocytes
por: Spitzer, Philipp, et al.
Publicado: (2010)

The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes
por: Oberstein, Timo Jan, et al.
Publicado: (2021)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
por: Hellwig, Konstantin, et al.
Publicado: (2015)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006)

Modified serpinA1 as risk marker for Parkinson’s disease dementia: Analysis of baseline data
por: Halbgebauer, Steffen, et al.
Publicado: (2016)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia
por: Jesse, Sarah, et al.
Publicado: (2012)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
por: Sjödin, Simon, et al.
Publicado: (2019)

A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation
por: Gaetani, Lorenzo, et al.
Publicado: (2018)

Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial
por: Rosenberg, Anna, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

Detection and Differentiation of Threonine- and Tyrosine-Monophosphorylated Forms of ERK1/2 by Capillary Isoelectric Focusing-Immunoassay
por: Kraus, Inga, et al.
Publicado: (2015)

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
por: Soininen, Hilkka, et al.
Publicado: (2017)

36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
por: Soininen, Hilkka, et al.
Publicado: (2020)

A Practical Guide to Immunoassay Method Validation
por: Andreasson, Ulf, et al.
Publicado: (2015)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
por: Pikwer, Andreas, et al.
Publicado: (2017)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia
por: Hüttenrauch, Melanie, et al.
Publicado: (2018)

Synaptic dysfunction and septin protein family members in neurodegenerative diseases
por: Marttinen, Mikael, et al.
Publicado: (2015)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

NEAT1 on the Field of Parkinson’s Disease: Offense, Defense, or a Player on the Bench?
por: Boros, Fanni Annamária, et al.
Publicado: (2021)

Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease
por: Spitzer, Philipp, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qtleuq4c8h6s22pknib4thtnfg